Germ line<i>DDX41</i>mutations define a unique subtype of myeloid neoplasmsHideki Makishima, Jaroslaw P. Maciejewski, Hisashi Tsurumi et al.|Blood|2022Cited by 142
Molecular MRD is strongly prognostic in patients with <i>NPM1</i>-mutated AML receiving venetoclax-based nonintensive therapyJad Othman, Richard Dillon, Michael J. Austin et al.|Blood|2023Cited by 65
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AMLJad Othman, Richard Dillon, Steven Knapper et al.|Leukemia|2023Cited by 48
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> MutationsNigel H. Russell, Shankara Paneesha, Ashok Roy et al.|Journal of Clinical Oncology|2024Cited by 40
Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHSJad Othman, Richard Dillon, Michael J. Austin et al.|Blood Neoplasia|2024Cited by 36